Robotic Gait Training + Physical Therapy for Cerebral Palsy
Trial Summary
What is the purpose of this trial?
Robot assisted gait training is seen as a promising intervention for improving the walking abilities of children with cerebral palsy, but research to support its effectiveness compared to best practice physical therapy is lacking. This research consists of a randomized controlled trial (RCT) and a qualitative descriptive study that is linked with the RCT. The goal of the RCT is to compare: 1) a walking training program with the Lokomat® robotic device (LOK), 2) a functional physical therapy program (fPT) that includes activities to enhance balance/co-ordination/endurance and advanced motor skills conducted over 'real ground', 3) a combined Lokomat® + functional physical therapy (LOK+fPT) program, and 4) a regular maintenance therapy condition (CONT) for ambulatory children and youth with CP (aged 5- 18 years). The three intervention programs will consist of sixteen 50-minute sessions given twice weekly over 8 to 10 weeks. The primary objective of the RCT is to compare the four groups with respect to walking-related motor skills as measured by the Gross Motor Function Measure. The secondary objectives are to compare each intervention's impact on walking abilities, individualized goals, fitness, balance, physical activity levels, child's belief in ability to do physical activity, participation and quality of life. The investigators will also evaluate the extent of carryover or progress 3 months after the intervention. The qualitative part of the study will consist of interviews of children and parents after they have finished the study intervention. The information from the interviews will assist us with interpretation of the outcome results (areas of impact and amount of change) from the RCT. In particular, the interviews will 1) provide insight into their experiences with the trial interventions, 2) identify the mobility-related outcomes that are important to families and the factors that influence their preferences, and 3) explain the family values, experiences and contextual factors that influenced participation in the study. This research will provide information needed to allow clinicians and families to make informed choices about Lokomat therapy and physical therapy options in relation to their child's functional goals and abilities.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, regular physical therapy and other gross motor mobility therapies must be discontinued during the trial, except for home programs like stretching and light exercise.
What data supports the effectiveness of the treatment Robotic Gait Training + Physical Therapy for Cerebral Palsy?
Research shows that robotic-assisted gait training, like the Lokomat, can improve balance and walking abilities in children with cerebral palsy by enhancing postural and locomotor functions. Studies have found significant improvements in gait parameters and motor skills after using this treatment, indicating its potential benefits for children with cerebral palsy.12345
Is robotic gait training safe for children with cerebral palsy?
How does robotic gait training with Lokomat differ from other treatments for cerebral palsy?
Robotic gait training with Lokomat is unique because it uses a robotic exoskeleton to help children with cerebral palsy practice walking, allowing for longer and more varied training sessions compared to traditional physical therapy. This approach can improve balance and walking patterns by providing consistent support and guidance, which may not be possible with conventional therapy or treadmill training alone.12347
Research Team
Lesley Wiart, PhD
Principal Investigator
University of Alberta
Virginia Wright, PhD
Principal Investigator
Holland Bloorview Kids Rehabilitation Hospital
Eligibility Criteria
This trial is for children and youth aged 5-18 with Cerebral Palsy, specifically those who can follow instructions for a walking test and participate in active physical therapy. They should be able to communicate discomfort and have certain levels of hip and knee flexibility. Participants must commit to multiple sessions over several weeks but cannot receive other mobility therapies during the study.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either LOK, fPT, or LOK+fPT interventions, consisting of two 50-minute sessions per week over 8 to 10 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 3 months post-intervention
Qualitative Interviews
Interviews with children and parents to gather insights on experiences and outcomes
Treatment Details
Interventions
- Gait focused physical therapy (Behavioural Intervention)
- Lokomat (Robotics)
- Regular Maintenance Therapy (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alberta
Lead Sponsor
Bill Flanagan
University of Alberta
Chief Executive Officer since 2020
LLB from University of Toronto, LLM from Columbia University
Dr. Verna Yiu
University of Alberta
Chief Medical Officer since 2012
MD from University of Alberta, Fellowship in Pediatric Nephrology at Harvard University
Northeastern University
Collaborator
Jared Auclair
Northeastern University
Chief Executive Officer
PhD in Biomedical Science from the University of Massachusetts Medical School
Anantdeep Kaur
Northeastern University
Chief Medical Officer since 2023
Master’s and Doctorate in Biotechnology from the University of Technology Sydney
Holland Bloorview Kids Rehabilitation Hospital
Collaborator
Julia Hanigsberg
Holland Bloorview Kids Rehabilitation Hospital
Chief Executive Officer since 2015
Law degrees from McGill University and Columbia Law School
Dr. Golda Milo-Manson
Holland Bloorview Kids Rehabilitation Hospital
Chief Medical Officer since 2010
MD from University of Toronto
Shirley Ryan AbilityLab
Collaborator
Dr. Pablo Celnik
Shirley Ryan AbilityLab
Chief Executive Officer since 2023
MD from University of Buenos Aires Faculty of Medical Sciences
Dr. James Sliwa
Shirley Ryan AbilityLab
Chief Medical Officer since 2021
DO